

Eveline Barbieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9272998/publications.pdf>

Version: 2024-02-01

21
papers

773
citations

687363

13
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1229
citing authors

#	ARTICLE	IF	CITATIONS
1	MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2358-2365.	4.1	130
2	Low birth weight for gestational age and subsequent male gonadal function. <i>Journal of Pediatrics</i> , 2002, 141, 376-380.	1.8	129
3	A Genome-Wide Search for Promoters That Respond to Increased MYCN Reveals Both New Oncogenic and Tumor Suppressor MicroRNAs Associated with Aggressive Neuroblastoma. <i>Cancer Research</i> , 2011, 71, 3841-3851.	0.9	70
4	Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. <i>Angiogenesis</i> , 2011, 14, 255-266.	7.2	58
5	G-CSF Receptor Positive Neuroblastoma Subpopulations Are Enriched in Chemotherapy-Resistant or Relapsed Tumors and Are Highly Tumorigenic. <i>Cancer Research</i> , 2013, 73, 4134-4146.	0.9	55
6	Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo. <i>Neoplasia</i> , 2009, 11, 753-762.	5.3	51
7	Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma. <i>Cancer Research</i> , 2014, 74, 765-774.	0.9	47
8	A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma. <i>PLoS ONE</i> , 2013, 8, e79843.	2.5	34
9	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. <i>JCI Insight</i> , 2018, 3, .	5.0	28
10	MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. <i>Oncotarget</i> , 2018, 9, 20323-20338.	1.8	28
11	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6629-6639.	7.0	23
12	Restoration of the molecular clock is tumor suppressive in neuroblastoma. <i>Nature Communications</i> , 2021, 12, 4006.	12.8	22
13	Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. <i>Oncotarget</i> , 2017, 8, 57047-57057.	1.8	19
14	MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. <i>Nature Communications</i> , 2022, 13, .	12.8	18
15	Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples. <i>Scientific Reports</i> , 2016, 6, 37876.	3.3	17
16	CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. <i>Advanced Science</i> , 2021, 8, e2005047.	11.2	17
17	Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy. <i>Haematologica</i> , 2005, 90, 141-2.	3.5	9
18	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. <i>Neoplasia</i> , 2021, 23, 624-633.	5.3	8

#	ARTICLE	IF	CITATIONS
19	Inhibin B Levels in Adolescents and Young Adults with Type 1 Diabetes. Hormone Research in Paediatrics, 2002, 57, 205-208.	1.8	5
20	The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. International Journal of Molecular Sciences, 2021, 22, 6565.	4.1	5
21	Abstract A02: The epigenetic modifier CHAF1A opposes neuroblastoma differentiation via metabolic reprogramming. , 2015, , .		0